The latest financial statement is for the quarter ending 2025-12-31.
| Cash Flow | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|
| Net loss | - | -386,901 | -3,258,969 |
| Net income (loss) from continuing operations | 6,743,499 | - | - |
| Depreciation and amortization | -12,857 | 47,992 | 343,830 |
| Net loss from disposal of equipment | -1 | 61 | - |
| Gain from disposal of subsidiaries | 7,346,684 | - | - |
| Interest income | 9,206 | - | - |
| Prepaid expenses and other current assets | -710,972 | 58,958 | 2,685,519 |
| Accounts payable, accruals and other current liabilities | -99,499 | -232,574 | -117,661 |
| Lease obligations, net cash | - | 11,781 | -23,709 |
| Other non-current assets | 6,608 | -8,257 | 83,027 |
| Interest received | -9,206 | - | - |
| Net cash used in operating activities from continuing operations | -246,400 | - | - |
| Net cash used in operating activities from discontinued operations | -877,500 | - | - |
| Cash used in operating activities | -513,558 | -610,342 | -5,825,055 |
| Purchase of equipment | 12,906 | 1,771 | 31,650 |
| Net cash used in investing activities from continuing operations | -14,677 | - | - |
| Cash used in investing activities | -12,906 | -1,771 | -31,650 |
| Net proceeds from issuance of stock in ipo/(prepayments for ipo costs) | - | - | 5,493,800 |
| Proceeds from related parties-Major Stockholders | - | 9,456 | 296,507 |
| Repayments to related parties major stockholders | 17,941 | - | - |
| Repayments to related parties-Major Stockholders | - | 11,226 | 237,552 |
| Proceeds from related parties related corporations | 139,123 | - | - |
| Proceeds from related parties-Corporate Joint Venture | - | 449,232 | 981,546 |
| Net cash provided by financing activities from continuing operations | 121,182 | - | - |
| Repayments to related parties-Corporate Joint Venture | - | - | 600,000 |
| Net cash provided by financing activities from discontinued operations | 641,757 | - | - |
| Cash provided by financing activities | 315,477 | 447,462 | 5,934,301 |
| Effect of exchange rate on cash from continuing operations | -39,871 | -82,745 | 218,346 |
| Effect of exchange rate on cash from discontinued operations | 204,931 | - | - |
| Net change in cash, including cash from discontinued operations | -45,927 | -247,396 | 295,942 |
| Cash and cash equivalents at beginning of period | 2,656,519 | 2,903,915 | 2,607,973 |
| Cash and cash equivalents at end of period | 2,610,592 | 2,656,519 | 2,903,915 |
Advanced Biomed Inc. (ADVB)
Advanced Biomed Inc. (ADVB)